-transparent.png){kind=logo}
Eighteen patients with advanced renal cancer received a combination of IFN alpha 10 x 10(6) U/m2/Day (D) x 5D followed by Interleukin 2 (IL2) 18 x 10(6) UI/m2/D x 5 D. The median follow-up is 10 months. Four partial responses were observed lasting 7 to 13 months (22.2%). The clinical safety was satisfactory. The survival for responding patients is 12 months (median). The safety of treatment is an argument in favour of future trials in an attempt to demonstrate the benefit of combinations of biomodulators.
Related Publications
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
November 1989,
Pathologie-biologie,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
April 2002,
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
November 1987,
La Tunisie medicale,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
January 1970,
Journal d'urologie et de nephrologie,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
January 1988,
Journal d'urologie,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
January 1996,
Archivos espanoles de urologia,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
October 2005,
Cancer biotherapy & radiopharmaceuticals,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
October 2006,
Cancer biotherapy & radiopharmaceuticals,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
January 1993,
Annales d'urologie,
C Boaziz, and
J L Breau, and
J F Morère, and
E Raymond, and
M Moliard, and
L Israel
September 1964,
Journal d'urologie et de nephrologie,
